CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Bazedoxifene/Conjugated Estrogendrug
Likely dose
Bazedoxifene/Conjugated Estrogen 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03740009
NCT03740009Phase 4Completed
CompareCT.gov

Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause

University of North Carolina, Chapel Hill·interventional·Posted Nov 14, 2018·Updated May 10, 2022

In Brief

A Phase 4 clinical trial evaluating Bazedoxifene/Conjugated Estrogen for Perimenopausal Disorder and Depression. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women with depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPerimenopausal Disorder, Depression
CountriesUnited States
CollaboratorsFoundation of Hope, North Carolina

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedNov 14, 2018
Enrollment StartJan 2, 2019
Primary CompletionMay 17, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.6 years ago

Interventions

Bazedoxifene/Conjugated Estrogendrug

20 mg bazedoxifene/0.45mg conjugated estrogens tablets